InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-24 | 2026-04-27 | HRT FINANCIAL LP | 10% Owner | Sale | 29.4K | $0.28 | $8K | 88.4K | View ↗ | |
| 2026-04-23 | 2026-04-27 | HRT FINANCIAL LP | 10% Owner | Sale | 3,811 | $0.29 | $1K | 117.8K | View ↗ | |
| 2026-04-22 | 2026-04-23 | HRT FINANCIAL LP | 10% Owner | Sale | 12.0K | $0.30 | $4K | 121.6K | View ↗ | |
| 2026-04-21 | 2026-04-23 | HRT FINANCIAL LP | 10% Owner | Purchase | 72.9K | $0.33 | $24K | 133.6K | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Sales | $3K-97.6% | $134K-79.2% | $645K-30.9% | $934K+789.0% | $105K |
| Cost of goods sold | $3K-99.5% | $627K-17.1% | $757K-1.3% | $767K+883.3% | $78K |
| Gross profit (loss) | $268+100.1% | -$493K-342.0% | -$112K-166.9% | $167K+517.0% | $27K |
| General and administrative expenses $0 and $33,071in stock-based compensation, respectively | $16.0M-1.9% | $16.3M-12.5% | $18.6M+16.4% | $16.0M-27.6% | $22.1M |
| Research and development $10,000 and $6,712,663 in stock-based compensation, respectively | $3.2M-70.7% | $10.9M+53.9% | $7.1M-2.7% | $7.3M+44.1% | $5.0M |
| Sales and marketing $473,311 and $0 in stock-based compensation, respectively | $402K+103.2% | $198K-26.5% | $269K-85.4% | $1.8M | — |
| Total operating expenses | $19.6M-28.5% | $27.4M+5.5% | $26.0M+1.2% | $25.6M-38.9% | $42.0M |
| NET LOSS FROM OPERATIONS | -$19.6M+29.8% | -$27.9M-6.9% | -$26.1M-2.3% | -$25.5M+39.2% | -$41.9M |
| Interest expense | -$681K+83.7% | -$4.2M+0.2% | -$4.2M-457.1% | -$753K-707.9% | -$93K |
| Interest income | $200K+13667.5% | $1K-85.7% | $10K-82.3% | $57K+1749.3% | $3K |
| Amortization of debt discount | -$1.7M+46.2% | -$3.2M-44.7% | -$2.2M-43.2% | -$1.5M+16.9% | -$1.8M |
| Gain (loss) on note exchange agreement | -$209K | — | $52K | — | — |
| Change in fair value of derivative liability | $15K-96.5% | $415K | — | — | — |
| Change in fair value of Evofem warrants | $2.8M | — | — | — | — |
| Impairment of Evofem F-1 Preferred Stock | -$23.8M | — | — | — | — |
| Bargain purchase gain from purchase of Evofem convertible notes | $328K | — | — | — | — |
| Impairment of fixed assets | -$412K | — | — | — | — |
| Total other expense | -$23.2M-224.4% | -$7.2M-13.1% | -$6.3M-191.6% | -$2.2M+51.1% | -$4.4M |
| Net loss before income taxes | -$42.8M-22.2% | -$35.0M-8.1% | -$32.4M-17.1% | -$27.6M+40.4% | -$46.4M |
| NET LOSS | -$42.8M-22.2% | -$35.0M-8.1% | -$32.4M-17.1% | -$27.6M+40.4% | -$46.4M |
| Deemed Dividends | -$1.4M+76.5% | -$5.9M-1746.7% | -$320K | — | — |
| NET LOSS ATTRIBUTABLE TO NON-CONTROLLING INTEREST | -$1.1M-87.0% | -$574K-5869.7% | -$10K | — | — |
| NET LOSS ATTRIBUTABLE TO ADITXT, INC. & SUBSIDIARIES | -$43.1M-6.8% | -$40.4M-23.4% | -$32.7M-18.3% | -$27.6M+40.4% | -$46.4M |
| Net loss per share, basic (in Dollars per share) | -$1K+100.0% | -$22.1M-81811.4% | -$27K-4428.1% | -$597.12-392.8% | -$121.18 |
| Net loss per share, diluted (in Dollars per share) | -$1K+100.0% | -$22.1M-81811.4% | -$27K | — | — |
| Weighted average number of shares outstanding during the period, basic (in Shares) | $37K+1867650.0% | $2-99.8% | $1K-97.4% | $46K-87.9% | $382K |
| Weighted average number of shares outstanding during the period, diluted (in Shares) | $37K+1867650.0% | $2-99.8% | $1K | — | — |
| Net Loss | -$42.8M-22.2% | -$35.0M-8.1% | -$32.4M-17.1% | -$27.6M | — |
| Change in valuation of Evofem note | $1.3M | — | — | — | — |
| TOTAL COMPREHENSIVE LOSS | -$41.5M-18.6% | -$35.0M | — | — | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Aditxt announces 1-for-27 reverse stock split
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-27 Reverse Stock Split Effective at the Open of Trading on May 18, 2026
Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics’ RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients
Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer